PGS Sample Set (PSS): PSS000503

Phenotype Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing.
Sample Ancestry European

Sample Numbers

Total number
2,305 individuals
Detailed numbers
1,133 cases (49.15%)
1,172 controls
100.0% Male samples
Number of Cohort(s) 2
Sample distribution
Sample gender distribution

Cohort(s)

Cohort Short Name Cohort Full Name Previous/other/additional names (e.g. sub-cohorts)
AG Ambry Genetics
JHH Johns Hopkins Hospital